Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like they are back to full strength in their sales force. The next two quarters should be a strong rebound on sales--if not turning cash flow positive.
jmo
Alimera Sciences Inc. - Company Background:
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera Sciences’ management team are dedicated and focused to making Alimera a leading ophthalmic pharmaceutical company. Our team has demonstrated expertise through the extensive commercialization and development of ophthalmic products.
Market Capitalization: $35 million
Range - 52 week: $0.47 - $1.21
Current Price: $0.55
Trades on: Nasdaq Capital Markets
Ticker Symbol: ALIM
Website: www.alimerasciences.com
HIGHLIGHTS:
*Local Alpharetta-based Company
*Focused on Diseases affecting the back of the Eye/Retina
*Diseases not treated very well with existing therapies
*New Leadership team
*2018 Net Revenue was up 31% over 2017
*1st Qtr. 2019 Revenue up 34% compared to Q1 2018
*International Net Revenue up 118% to $6.1 million during Q1 '19
*National Pricing-Reimbursement obtained for ILUVIEN in France;recent recommendation of reimbursement in the United Kingdom(NICE)
*Launched Pilot Direct-to-Patient Marketing Campaign for ILUVIEN in the U.S. for diabetic macular edema (DME)
*$12 mm+ cash;
Nice move with healthy volume. ALIM is getting on a few more radar screens today.
News: $ALIM Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIEN(R) in Europe
- Indication for treatment of non-infectious posterior uveitis further supports the uniqueness of ILUVIEN to consistently and continuously deliver treatment to reduce the recurrence of inflammation - Regulatory process to now enter the national phase in which each member state finalizes...
Got this from https://marketwirenews.com/news-releases/alimera-sciences-announces-approval-received-in-the-mutual-recognition-procedure-for-new-indication-for-iluvien-r-in-europe-7867214.html
Alimera Sciences Reports Third Quarter 2018 Results
Record Net Revenue of $11.1 Million in Q3 2018; U.S. Net Revenue up 20%
Record U.S. End User Demand in Q3 2018
Net Loss and Adjusted EBITDA Loss Continue to Improve
ATLANTA, GA / ACCESSWIRE / November 5, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced financial results for the three months ended September 30, 2018. Alimera will host a conference call on November 6, 2018, at 9:00 a.m. ET to discuss these results.
"We are pleased with our progress in the third quarter of 2018, our highest quarter in both revenue and U.S. end user demand. Three years into the launch of ILUVIEN in the U.S., we continue to grow and anticipate continued momentum through the end of 2018 and into 2019," said Dan Myers, Alimera's Chief Executive Officer. "We are encouraged by the continued reduction of our net loss and adjusted EBITDA loss as we approach breakeven. We look forward to expanding the availability of and demand for ILUVIEN as we anticipate the addition of an indication for uveitis in Europe and launches of ILUVIEN by our distribution partners in Spain and France."
Third Quarter 2018 Financial Results
Consolidated Net Revenue
Consolidated net revenue increased 13% to approximately $11.1 million for the three months ended September 30, 2018, compared to approximately $9.8 million for the three months ended September 30, 2017. For the nine months ended September 30, 2018 consolidated net revenue increased 19% to approximately $31.9 million, compared to approximately $26.8 million for the nine months ended September 30, 2018.
U.S. Net Revenue
U.S. net revenue increased by 20% to approximately $8.5 million for three months ended September 30, 2018, compared to U.S. net revenue of approximately $7.1 million for the three months ended September 30, 2017. The increase was attributable to increased end user demand and increased sales to our distributors during the three months ended September 30, 2018.
End user demand, which represents units purchased by physicians and pharmacies from our distributors, was higher in the three months ended September 30, 2018, increasing 17% to 977 units compared to 837 units in the three months ended September 30, 2017.
The discrepancy between GAAP revenue and end user demand growth is due to the timing of distributor purchases from quarter to quarter. In the third quarter of 2018, Alimera's distributors purchased approximately 5% more units than they sold to end users, increasing their stock on hand during that quarter. In the third quarter of 2017, Alimera's distributors purchased approximately 3% more units than they sold to end users, increasing their stock on hand during that quarter.
International Net Revenue
Net revenue in Alimera's international segment was approximately $2.6 million for both the three months ended September 30, 2018 and 2017. Although overall net revenue remained flat, sales in the countries in Europe where we sell through distributors increased $370,000, while sales in the other countries in Europe where we sell directly decreased $360,000. The increase in our distributor markets was due to increased demand in the Middle East and Italy, and stocking orders by the Company's Spanish distributor in advance of a planned 2019 launch. The decrease in the direct markets was primarily attributable to a decrease in sales in Germany. Revenues from Alimera's international distributors comprise, depending upon the distribution arrangement, both upfront payments for inventory and a revenue share of the distributors' sales of product to end users. Revenues from Alimera's international distributors will fluctuate from quarter to quarter based upon the timing of the distributors' stocking practices.
Operating Expenses
Research, development and medical affairs expenses for the three months ended September 30, 2018 decreased by 48%, to approximately $2.8 million, compared to approximately $5.4 million for the three months ended September 30, 2017. The decrease was primarily attributable to a decrease of approximately $2.9 million related to a non-cash charge in the 2017 period for in-process Research and Development Expense to acquire the rights to Uveitis from EyePoint Pharmaceuticals expensed during the three months ended September 30, 2017.
General and administrative expenses for the three months ended September 30, 2018 increased by $100,000, or 3%, to approximately $3.4 million, compared to approximately $3.3 million for the three months ended September 30, 2017.
Sales and marketing expenses decreased by 8%, to $5.5 million for the three months ended September 30, 2018, compared to $6.0 million reported for the three months ended September 30, 2017. The decrease was primarily attributable to a $310,000 reduction in international personnel costs, and a $200,000 reduction in expenses associated with commercial support.
Total operating expenses were approximately $12.4 million for the three months ended September 30, 2018, compared to approximately $12.6 million for the three months ended September 30, 2017, a decrease of 2%. "Adjusted Operating Expenses," a non-GAAP financial measure defined below, were approximately $10.7 million for the three months ended September 30, 2018, compared to Adjusted Operating Expenses of approximately $10.6 million for the three months ended September 30, 2017, an increase of 1%.
Net Loss
Net loss for the three months ended September 30, 2018 was approximately $3.5 million, compared to a net loss of approximately $5.3 million for the three months ended September 30, 2017, an improvement of 34%.
Adjusted EBITDA
"Adjusted EBITDA," a non-GAAP financial measure defined below, was approximately a $520,000 loss for the three months ended September 30, 2018, compared to Adjusted EBITDA of approximately a $1.8 million loss for the three months ended September 30, 2017, an improvement of 71%.
Net Income (Loss) per Common Share
Basic net income per common share for the three months ended September 30, 2018 was $0.40 on 87,972,575 total weighted average shares outstanding, compared to basic net loss per share of $(0.08) on 68,430,856 total weighted average shares outstanding during the three months ended September 30, 2017. Diluted net income per common share for the three months ended September 30, 2018 was $0.39 on 88,108,280 total weighted average shares outstanding, compared to diluted net loss per share of $(0.08) on 68,430,856 total weighted average shares outstanding during the three months ended September 30, 2017. Net income for the three months ended September 30, 2018 was primarily attributable to the gain on the extinguishment of Alimera's Series B Convertible Preferred Stock resulting from its exchange in September 2018 for new Series C Convertible Preferred Stock which attributed $0.45 per share and $0.48 per share for the three and nine months ended September 30, 2018, respectively.
Non-GAAP Loss per Common Share
Basic and diluted "Non-GAAP Net Loss per Common Share," a non-GAAP financial measure defined below that reflects the elimination of the gain on the extinguishment of preferred stock, was $(0.05) for the three months ended September 30, 2018 on 70,038,411 weighted average shares outstanding, compared to $(0.08) on 68,430,856 weighted average shares outstanding during the three months ended September 30, 2017.
Cash and Cash Equivalents
As of September 30, 2018, Alimera had cash and cash equivalents of approximately $12.6 million.
Definitions of Non-GAAP Financial Measures
For purposes of this press release, "Adjusted Operating Expenses" is operating expenses minus depreciation, amortization, and stock-based compensation expenses. "Adjusted EBITDA" is earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains and losses from foreign currency exchange transactions, gains and losses from the change in the fair value of derivative warrant liability and losses on extinguishment of debt. "Non-GAAP Net Loss per Common Share" is Net Loss, after the elimination of the gain on the extinguishment of Alimera's Series B Convertible Preferred Stock resulting from its exchange in September 2018 for new Series C Convertible Preferred Stock, divided by weighted average common shares outstanding. Alimera provides non-GAAP financial information because it believes this information can enhance an overall understanding of its financial performance when considered together with GAAP figures. Refer to the sections of this press release entitled "Non-GAAP Financial Measures" and "Reconciliation of GAAP Measures to Non-GAAP Adjusted Measures," which includes Adjusted Operating Expenses, Adjusted EBITDA, and Non-GAAP Net Loss per Common Share.
Conference Call to be Held November 6, 2018
A conference call will be hosted by Dan Myers, Chief Executive Officer, and Rick Eiswirth, President and Chief Financial Officer, to discuss the results. The call will be held at 9:00 a.m. ET, on November 6, 2018. Please refer to the information below for conference call dial-in information and webcast registration.
Conference date: November 6, 2018, 9:00 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences Third Quarter 2018 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on Alimera's website, www.alimerasciences.com, under "Investor Relations."
About Alimera Sciences
News out! Timber!
TIMBER!!!
.09 coming !
Falling knife !!!.0001
.80 going !
degrees ?????
Timber !!! .85 today!!!
Alimera Sciences, In (ALIM)
1.115 ? 0.005 (0.45%)
Volume: 16,182 @ 11:03:31 AM EDT ET
Bid Ask Day's Range
1.11 1.12 1.1 - 1.12
ALIM Detailed Quote
Alimera Sciences, In (ALIM)
1.11 ? 0.0 (0.00%)
Volume: 0 @- ET
Bid Ask Day's Range
0.792 1.14 - - -
ALIM Detailed Quote
What happens,when the nucleus leaves the Company?!!!
Shorts going to take this down ! .01
Hit the lights !
Alimera Sciences, In (ALIM)
1.22 ? 0.06 (5.17%)
Volume: 166,523 @ 4:00:00 PM EST ET
Bid Ask Day's Range
0.1 1.41 1.155 - 1.22
ALIM Detailed Quote
Don't worry . .65
Trying to get some @ 1.30, let's see if he bites... GLTA!
thank you/ Alimera Sciences, In (ALIM)
1.31 ? 0.0 (0.00%)
Volume: 31,806 @ 12:54:28 PM EST ET
Bid Ask Day's Range
1.29 1.31 1.291 - 1.32
ALIM Detailed Quote
Alimera Sciences, In (ALIM)
1.4 ? 0.03 (2.19%)
Volume: 97,309 @ 3:20:21 PM EDT ET
Bid Ask Day's Range
1.39 1.4 1.37 - 1.41
ALIM Detailed Quote
Alimera Sciences, In (ALIM)
1.4 ? -0.01 (-0.71%)
Volume: 192,685 @ 4:00:00 PM ET
Bid Ask Day's Range
1.32 1.55 1.38 - 1.42
ALIM Detailed Quote
ALIM News: Quarterly Report (10-q) 05/11/2017 09:13:51 AM
ALIM News: Current Report Filing (8-k) 05/09/2017 06:07:19 AM
ALIM News: Alimera Sciences Reports First Quarter 2017 Financial Results 05/08/2017 04:58:23 PM
ALIM News: Additional Proxy Soliciting Materials (definitive) (defa14a) 05/03/2017 04:41:49 PM
ALIM News: Revised Proxy Soliciting Materials (definitive) (defr14a) 05/03/2017 04:37:29 PM
Alimera Sciences, In (ALIM)
1.48 ? 0.0 (0.00%)
Volume: 0 @- ET
Bid Ask Day's Range
1.2 1.65 - - -
ALIM Detailed Quote
$ALIM
http://www.chartmill.com/stockcharts.php?ticker=alim
[-chart]www.chartmill.com/chartsrv/chart.php?width=800&height=350&sheight=120&id=11479&timeframe=DAILY&elements=0&type=CANDLES&cl=F&wi=3,200,16711680&wi=3,50,255&wi=1[/chart]
I listened to the CC this morning.E Europe
is ahead in orders and more length of experience with US Lagging behind.
The Cincinnati retinal doctor gave a good insight in what he does in the process to use Illivun starting with anti vegf drugs
and other drugs to determine drug reaction before using Illuvin for diabetic patients.I think based upon the longer experience in the EU of ILuven bodes well
for clearing the decks of patients needing
injection every several weeks to 3 years so that more new consults can be treated
and more. profitable.The doctors clinic did 25,000 injections a year. Also he mentioned that the financial handling charge for administering Oralezix will end
All this bodes well for increased usage in the US and Canada.
The mouse ran up the clock.
Alimera Sciences, In (ALIM)
1.39 ? 0.0 (0.00%)
Volume: 0 @- ET
Bid Ask Day's Range
1.32 1.53 - - -
ALIM Detailed Quote
interesting stuff/ $ALIM
Tick tock (.)
Followers
|
33
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1033
|
Created
|
12/26/10
|
Type
|
Free
|
Moderators |
Alimera Sciences, Inc. (Alimera) is committed to conducting its business in compliance with all applicable laws, rules, and regulations and the highest standards of ethical conduct. To this end, we have established and will maintain a Comprehensive Compliance Program (“Compliance Program”) in accordance with the OIG Compliance Program Guidance for Pharmaceutical Manufacturers (the “OIG Guidance”) published by the Office of Inspector General, U.S. Department of Health and Human Services. Our Compliance Program is a key component of our commitment to adhering to the highest standards of corporate responsibility and fostering a culture of compliance that places a premium on doing business with integrity. Our Program also incorporates the Code on Interactions with Healthcare Professionals published by the Pharmaceutical Research and Manufacturers of America.
We have designed our Compliance Program to (1) prevent, detect, and remediate violations of applicable laws, rules, and regulations, as well as Alimera’s policies and procedures and (2) promote a culture of the highest ethics within the company. It is Alimera’s expectation that employees will comply with our Code of Business Conduct and the policies and procedures established in support of that Code. As the OIG Guidance recognizes, however, the implementation of a Compliance Program cannot guarantee the elimination of improper employee conduct.
As recognized in the OIG Guidance, we have tailored our Compliance Program — the fundamental elements of which we have described below – to fit the unique environment of our company. Moreover, our Compliance Program is dynamic and we regularly review and enhance our Program to meet our evolving compliance needs.
You may obtain a copy of this Compliance Program description by calling 1-844-445-8843.
Compliance Officer. Alimera has appointed a Compliance Officer who is charged with developing, implementing, and monitoring the Compliance Program. We will ensure that the Compliance Officer has the ability to exercise independent judgment and, as necessary, effectuate change within the company. The Compliance Officer reports to the President and Chief Executive Officer of Alimera, is a member of Alimera’s Executive Management team, and has direct access to the Alimera Board of Directors.
Compliance Committee. Alimera has established a Compliance Committee made up of Alimera senior management. The role of the Compliance Committee is to advise and assist the Compliance Officer in the development, implementation, and ongoing oversight of the Compliance Program. The Compliance Committee meets on a regular basis to identify and manage areas of risk and areas of critical focus for the Compliance Program.
Alimera has established written policies and procedures, including our Code of Business Conduct, which articulates our fundamental principles and values and provides a framework for ethical conduct within our company. The Code of Business Conduct establishes our expectation that management, employees, and agents of Alimera act in accordance with all applicable laws, rules, and regulations; Alimera’s policies and procedures; and the highest standards of ethics.
In accordance with California law, Alimera has established an annual spending limit for certain promotional activities directed toward healthcare professionals who prescribe or may influence prescribing in California. At the present time our annual, per-prescriber spending limit is $1,500. Examples of items that fall within this spending limit are occasional modest meals in connection with informational presentations and educational items.
This annual spending limit does not include payments to healthcare professionals for bona fide consulting or other services.
It is Alimera’s policy to not provide any item of value to any healthcare professional with the intent of influencing that healthcare professional’s prescribing habits.
A crucial element of our Compliance Program is the education and training of our employees on their legal and ethical obligations under applicable laws, rules, regulations, and company policies and procedures. Alimera regularly communicates our policies and procedures to promote a thorough understanding of the company’s expectations and regularly reviews and updates our training initiatives.
Alimera actively fosters dialogue between management and employees. Our goal is that all employees should know to whom to turn when seeking answers to questions or reporting possible violations of company policies or procedures, and understand that they can make such reports without fear of retaliation. To that end, we have adopted open-door and non-retaliation policies. We have a toll-free compliance helpline to which employees of Alimera may anonymously raise questions or report any concerns or suspected violations of applicable laws, rules, regulations, or Alimera policies or procedures.
Alimera’s Compliance Program includes monitoring and auditing to evaluate adherence to Alimera’s policies and procedures.
We note that, in accordance with the OIG Guidance, the nature, extent, and frequency of our compliance monitoring and auditing
may vary according to new regulatory requirements, changes in business practices, and other considerations.
When Alimera becomes aware of potential violations of applicable laws, rules, or regulations or company policies or procedures,
the company will promptly investigate such matters and make a determination as to whether the facts substantiate the existence of a violation.
Alimera will document the conduct of such investigations.
While each substantiated violation will be considered on a case-by-case basis, where appropriate we will utilize disciplinary action consistent
with company policy to address violative conduct and to deter future violations.
We will also work to determine the root cause of the violation and assess whether the violation is due to gaps in company policies or procedures
and take appropriate corrective action designed to prevent future violations.
Alimera Sciences, Inc. hereby declares that, to the best of our knowledge, information, and belief,
and based upon our good-faith understanding of the statutory requirements, we have, as of March 3, 2015,
established a Comprehensive Compliance Program that is in material compliance with the requirements of California Health and Safety Code §§ 119400-119402.
While Alimera’s Comprehensive Compliance Program cannot completely eliminate the possibility that an individual employee will engage in improper conduct,
our Program is reasonably designed to prevent and detect violations of applicable laws, rules, and regulations, as well as our own internal policies and procedures.
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |